Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

新一代EGFR-TKIs及ALK-TKIs在非小细胞肺癌的临床研究进展

赖军明,林红,罗辉,胡爽

Acta Academiae Medicinae Jiangxi（2018）

Cited 1|Views21
No score
Abstract
肺癌的发病率及病死率在我国均是第1位,其中非小细胞肺癌(non-small cell lung cancer,NSCLC)是最常见的组织学类型,约占总数的80％～85％[1].晚期NSCLC的传统治疗模式是含铂双联化疗,中位生存期(media overall survival,mOS)约8个月,2年OS率为12％,但治疗效果并不是很理想[2].近年来,晚期NSCLC的分子靶向治疗的快速发展,从过去单纯的病理类型指导下的化疗转变为驱动基因指导下的分子靶向治疗,肺癌治疗经历了翻天覆地的变化.
More
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined